290 results on '"Girnita, Leonard"'
Search Results
2. IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma
3. Correction: The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway
4. Correction: IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma
5. Editorial Expression of Concern: Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene
6. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling
7. Genome-Wide Screen for MicroRNAs Reveals a Role for miR-203 in Melanoma Metastasis
8. Mdm2-Dependent Ubiquitination and Degradation of the Insulin-like Growth Factor 1 Receptor
9. Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
10. Supplementary table 5 from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
11. Supplementary figure 1 from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
12. Supplementary table 6 from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
13. Supplementary table 2 from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
14. Supplementary figure 2 from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
15. Supplementary table 1 from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
16. Supplementary Materials and Methods and Supplementary Figure and Table Legends from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
17. Supplementary table 3 from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
18. Supplementary table 4 from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
19. Data from Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism
20. Correction:IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma (Oncogene, (2022), 41, 4, (600-611), 10.1038/s41388-021-02111-x)
21. The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?
22. Editorial: DNA damage response pathways meet endocrine systems
23. Correction: The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway
24. Blurring Boundaries: Receptor Tyrosine Kinases as functional G Protein-Coupled Receptors
25. Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression
26. Editorial Expression of Concern: Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene
27. β-Arrestin—biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma
28. Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor
29. Differential Regulation of IGF-1 and Insulin Signaling by GRKs
30. Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation
31. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease
32. Can beta-arrestin isoforms control response of melanoma cells to chemotherapy?
33. β-arrestins as key regulators of response to p53 reactivation drugs in melanoma: 1270
34. Aberrant intracellular IGF-1R β-subunit makes receptor knockout cells ( IGF1R -/-) susceptible to oncogenic transformation
35. IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma
36. 26653 Can β-arrestin isoforms control response of melanoma cells to chemotherapy?
37. β-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle Progression
38. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway
39. Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene
40. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
41. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
42. IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R−)
43. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells
44. Cutaneous melanoma—The Swedish perspective
45. Inhibition of G Protein–Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth
46. The tale of a tail: The secret behind IGF-1R’s oncogenic power
47. β-Arrestin Is Crucial for Ubiquitination and Down-regulation of the Insulin-like Growth Factor-1 Receptor by Acting as Adaptor for the MDM2 E3 Ligase
48. Malignant solitary fibrous tumour of the orbit
49. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications
50. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.